NEORTESBIO's cutting-edge technology is centered around vessel normalization, which is achieved through the use of monoclonal antibodies, specifically Tri-VasTrap. In tissues with abnormal and leaky blood vessels, such as those found in tumors, pathogenic antagonists are present at elevated levels. These antagonists weaken the junctions between endothelial cells, which are the cells that line the interior surface of blood vessels, and cause detachment of pericytes, which are specialized cells that wrap around the blood vessels.
The result of these events is the formation of leaky and abnormal vessels, which can hinder the delivery of essential nutrients and oxygen to the surrounding tissue. Tri-VasTrap is designed to specifically bind to these pathogenic antagonists, transforming them into potent agonists. This conversion strengthens the junctions between endothelial cells, prevents pericyte detachment, and ultimately leads to vessel normalization.
By inducing vessel normalization, Tri-VasTrap improves blood flow in the affected tissues and enhances the delivery of therapeutic agents. This can help to reduce the spread of disease and improve the effectiveness of cancer treatments. Overall, NEORTESBIO's Tri-VasTrap technology represents a promising avenue for the development of more effective and targeted therapies for a range of diseases.
NEORTESBIO's main areas of focus are ocular diseases, specifically wet age-related macular degeneration (wetAMD) and diabetic retinopathy (DR), as well as solid tumors that are caused by abnormal blood vessel growth. In addition to these, the company also targets other diseases that are induced by abnormal vessels.
The technology developed by NEORTESBIO has the potential to greatly reduce the burden of ocular injections in patients suffering from diseases caused by abnormal leaky blood vessels. By using this technology, patients can receive effective treatment for wetAMD and DR without the need for frequent injections, resulting in a significant improvement in their quality of life and reducing the overall cost of care.
NEORTESBIO's technology is also promising in the field of solid tumor treatment, as it has the potential to increase the effectiveness of existing anticancer drugs such as chemotherapy, immune checkpoint inhibitors (ICI), and cell therapy. By targeting the abnormal blood vessels that contribute to tumor growth, NEORTESBIO's treatments can help to maximize the efficacy of these existing treatments, making them the backbone of solid tumor therapy. This breakthrough technology represents a significant step forward in the battle against cancer, providing new hope to patients and their families.
Overall, NEORTESBIO's innovative technology has the potential to revolutionize the treatment of a variety of challenging diseases, delivering significant benefits to patients and healthcare providers alike.